Innovations Advanced by M&A
Innovations Advanced by M&A: The Partnerships Driving Progress for Patients
Partnerships and collaboration play a critical role in fostering a vibrant U.S. life sciences ecosystem. Mergers and acquisitions are central to this ecosystem, allowing companies of all sizes to combine their complementary strengths to bring innovation to American patients.
Innovations Advanced by M&A: A First-in-Class Treatment for Pulmonary Arterial Hypertension
Merck’s 2021 acquisition of Acceleron Pharma is one example of how M&A can help bring new treatments to market and support continued innovation.
Innovations Advanced by M&A: A New Therapy to Slow Geographic Atrophy Progression
Astellas’ 2023 acquisition of Iveric Bio is one of many examples demonstrating how M&A can help support the transition from initial development to commercialization and continued innovation.
Innovations Advanced by M&A: A New Treatment for Hyperkalemia
AstraZeneca’s acquisition of ZS Pharma helped bring a treatment for hyperkalemia to patients globally.
Innovations Advanced by M&A: A New Medicine Treating Anemia for Patients with Myelofibrosis
GlaxoSmithKline (GSK)’s 2022 acquisition of Sierra Oncology combined Sierra’s specialization in developing targeting therapies for rare blood cancers with GSK’s global scale, regulatory experience and commercialization capabilities — leading to approval of the only first-line medicine to treat myelofibrosis patients who have anemia.
Innovations Advanced by M&A: A New Therapy for Ulcerative Colitis
The acquisition of Arena Pharmaceuticals by Pfizer in 2022 enabled the development and commercialization of Velsipity (etrasimod), an innovative therapy for moderate to severe ulcerative colitis (UC).
Innovations Advanced by M&A: A First-in-Class Therapy for Myasthenia Gravis
The 2020 acquisition of Momenta Pharmaceuticals by Johnson & Johnson (J&J) was critical to advancing IMAAVY (nipocalimab), a first-in-class therapy for generalized myasthenia gravis (gMG).
Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis
For many early-stage life sciences companies, mergers and acquisitions (M&A) represent a critical path. M&A helps companies unlock the complementary resources and expertise that help advance a new therapy from the lab to patients at scale. For example, Dermira’s acquisition by Eli Lilly & Co. helped bring Ebglyss, a novel monoclonal antibody treatment, to patients living with moderate-to-severe atopic dermatitis (AD).
Innovations Advanced by M&A: A First-in-Class Therapy for Chronic Graft-Versus-Host Disease
Mergers and acquisitions (M&A) serve as a critical bridge, enabling innovative companies of all sizes to partner and pair their promising biopharmaceutical discoveries with the resources and expertise needed to turn them into approved medicines for patients.
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers
Life sciences companies of all sizes rely on mergers and acquisitions (M&A) to focus on what they do best, and then combine complementary resources and expertise to quickly and efficiently advance new treatments and cures to consumers. In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.